Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developin… Read more
Candel Therapeutics Inc (CADL) - Total Assets
Latest total assets as of September 2025: $93.60 Million USD
Based on the latest financial reports, Candel Therapeutics Inc (CADL) holds total assets worth $93.60 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Candel Therapeutics Inc - Total Assets Trend (2019–2024)
This chart illustrates how Candel Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Candel Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Candel Therapeutics Inc's total assets of $93.60 Million consist of 97.1% current assets and 2.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 96.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Candel Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Candel Therapeutics Inc's current assets represent 97.1% of total assets in 2024, a decrease from 98.5% in 2019.
- Cash Position: Cash and equivalents constituted 96.1% of total assets in 2024, up from 11.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Candel Therapeutics Inc Competitors by Total Assets
Key competitors of Candel Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Candel Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Candel Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Candel Therapeutics Inc is currently not profitable relative to its asset base.
Candel Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.25 | 1.18 | 7.46 |
| Quick Ratio | 8.25 | 1.18 | 7.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $79.20 Million | $ 2.82 Million | $ 30.43 Million |
Candel Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Candel Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.69 |
| Latest Market Cap to Assets Ratio | 2.30 |
| Asset Growth Rate (YoY) | 159.4% |
| Total Assets | $106.87 Million |
| Market Capitalization | $245.32 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Candel Therapeutics Inc's assets at a significant premium ( 2.30x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Candel Therapeutics Inc's assets grew by 159.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Candel Therapeutics Inc (2019–2024)
The table below shows the annual total assets of Candel Therapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $106.87 Million | +159.38% |
| 2023-12-31 | $41.20 Million | -47.53% |
| 2022-12-31 | $78.52 Million | -11.98% |
| 2021-12-31 | $89.20 Million | +133.02% |
| 2020-12-31 | $38.28 Million | -16.60% |
| 2019-12-31 | $45.90 Million | -- |